Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

unknown2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

unknown250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
unknownnot_applicable

Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.

NCT04115527
completednot_applicable

Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA

NCT01215071
unknownnot_applicable

Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma

NCT02928081
completed

Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer

NCT02156414

Clinical Trials (4)

Showing 4 of 4 trials
NCT04115527Not Applicable

Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.

Unknown
NCT01215071Not Applicable

Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA

Completed
NCT02928081Not Applicable

Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma

Unknown
NCT02156414

Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4